1. Home
  2. DV vs ZYME Comparison

DV vs ZYME Comparison

Compare DV & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleVerify Holdings Inc.

DV

DoubleVerify Holdings Inc.

HOLD

Current Price

$13.31

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.40

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DV
ZYME
Founded
2008
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
DV
ZYME
Price
$13.31
$27.40
Analyst Decision
Buy
Strong Buy
Analyst Count
15
11
Target Price
$16.37
$38.90
AVG Volume (30 Days)
4.5M
499.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.12
N/A
Revenue
$748,291,000.00
$105,965,000.00
Revenue This Year
$12.68
$183.10
Revenue Next Year
$9.75
N/A
P/E Ratio
$110.83
N/A
Revenue Growth
13.92
38.87
52 Week Low
$7.61
$13.60
52 Week High
$16.44
$29.75

Technical Indicators

Market Signals
Indicator
DV
ZYME
Relative Strength Index (RSI) 69.02 73.09
Support Level $10.03 $22.10
Resistance Level $13.36 $29.75
Average True Range (ATR) 0.08 1.10
MACD -0.01 0.57
Stochastic Oscillator 97.01 99.52

Price Performance

Historical Comparison
DV
ZYME

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: